JP2009513643A - 少なくとも１つの保護されたチオール領域を有するアルブミンベースコロイド組成物、その製造方法および使用方法 - Google Patents

少なくとも１つの保護されたチオール領域を有するアルブミンベースコロイド組成物、その製造方法および使用方法 Download PDF

Info

Publication number
JP2009513643A
JP2009513643A JP2008537869A JP2008537869A JP2009513643A JP 2009513643 A JP2009513643 A JP 2009513643A JP 2008537869 A JP2008537869 A JP 2008537869A JP 2008537869 A JP2008537869 A JP 2008537869A JP 2009513643 A JP2009513643 A JP 2009513643A
Authority
JP
Japan
Prior art keywords
albumin
peg
composition
alb
dye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008537869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513643A5 (https=
Inventor
ラゲブ、エイ．アサリー
ジェイ．デイビッド、ディグナム
ジョセフ、アイ．シャピロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical University Of Ohio At Toledo
Original Assignee
Medical University Of Ohio At Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical University Of Ohio At Toledo filed Critical Medical University Of Ohio At Toledo
Publication of JP2009513643A publication Critical patent/JP2009513643A/ja
Publication of JP2009513643A5 publication Critical patent/JP2009513643A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2008537869A 2005-10-25 2006-10-24 少なくとも１つの保護されたチオール領域を有するアルブミンベースコロイド組成物、その製造方法および使用方法 Pending JP2009513643A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/258,646 US7345150B2 (en) 2002-03-26 2005-10-25 Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
PCT/US2006/041432 WO2007050581A2 (en) 2005-10-25 2006-10-24 An albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use

Publications (2)

Publication Number Publication Date
JP2009513643A true JP2009513643A (ja) 2009-04-02
JP2009513643A5 JP2009513643A5 (https=) 2009-12-17

Family

ID=37968466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008537869A Pending JP2009513643A (ja) 2005-10-25 2006-10-24 少なくとも１つの保護されたチオール領域を有するアルブミンベースコロイド組成物、その製造方法および使用方法

Country Status (5)

Country Link
US (2) US7345150B2 (https=)
EP (1) EP1940474A4 (https=)
JP (1) JP2009513643A (https=)
CA (1) CA2627155A1 (https=)
WO (1) WO2007050581A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520094A (ja) * 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345150B2 (en) * 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
US8036489B2 (en) * 2005-07-07 2011-10-11 Shutterfly, Inc. Systems and methods for creating photobooks
US9624259B2 (en) * 2007-04-16 2017-04-18 Regentis Biomaterials Ltd. Compositions and methods for scaffold formation
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
US20120010144A1 (en) * 2009-04-03 2012-01-12 Ragheb Assaly Peg-albumin composition having at least one protected thiol region as a platform for medications
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
JP2018501814A (ja) 2014-11-11 2018-01-25 クララ フーズ カンパニー 卵白タンパク質産生のための方法および組成物
US12096784B2 (en) 2019-07-11 2024-09-24 Clara Foods Co. Protein compositions and consumable products thereof
BR112022000545A2 (pt) 2019-07-11 2022-04-05 Clara Foods Co Composições de proteína e produtos de consumo destas
US10927360B1 (en) 2019-08-07 2021-02-23 Clara Foods Co. Compositions comprising digestive enzymes
RU2753589C1 (ru) * 2020-12-08 2021-08-18 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" (НИИ КПССЗ) Способ прогнозирования полиорганной недостаточности после операций на сердце, выполненных в условиях искусственного кровообращения

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10506550A (ja) * 1994-09-26 1998-06-30 ザ・ジョーンズ・ホプキンス・ユニバーシティ 眼における脈絡膜の血流および迷入血管構造の改善された視覚化
US20030004105A1 (en) * 2001-03-27 2003-01-02 Assaly Ragheb A. Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
US20050187139A1 (en) * 2002-03-26 2005-08-25 Medical College Of Ohio Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
US20060057070A1 (en) * 2002-03-26 2006-03-16 Medical University Of Ohio At Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2727027A (en) * 1955-12-13 Process for preparing oxyalkylated
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL47468A (en) * 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
US5077222A (en) * 1988-09-30 1991-12-31 Miles Inc. Method for assaying for proteins using a dual indicator reagent composition
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATA194989A (de) * 1989-08-17 1990-04-15 Koller Ernst Verfahren zum nachweis und zur bestimmung von humanserumalbumin in biologischen fluessigkeiten mit hilfe fluorogener cyanin-farbstoffe
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
ES2172573T3 (es) * 1993-12-01 2002-10-01 Bioartificial Gel Technologies Inc Hidrogel basado en albumina.
US5583114A (en) * 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5704358A (en) * 1994-11-22 1998-01-06 The Trustees Of Columbia University In The City Of New York Method and apparatus for diagnosing capillary leak
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5952009A (en) * 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
WO1998009647A2 (en) * 1996-09-06 1998-03-12 Medarex, Inc. Cyanidin compositions and therapeutic and diagnostic uses therefor
US6129912A (en) * 1997-09-26 2000-10-10 Uab Research Foundation Polyethylene glycol-protein compositions which reduce the antigenic display of red blood cells
WO2000023101A1 (en) * 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10506550A (ja) * 1994-09-26 1998-06-30 ザ・ジョーンズ・ホプキンス・ユニバーシティ 眼における脈絡膜の血流および迷入血管構造の改善された視覚化
US20030004105A1 (en) * 2001-03-27 2003-01-02 Assaly Ragheb A. Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
US20060166886A1 (en) * 2001-03-27 2006-07-27 Medical College Of Ohio Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
US20050187139A1 (en) * 2002-03-26 2005-08-25 Medical College Of Ohio Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
US20060057070A1 (en) * 2002-03-26 2006-03-16 Medical University Of Ohio At Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520094A (ja) * 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
JP2017206513A (ja) * 2011-05-27 2017-11-24 バクスアルタ ゲーエムベーハー 増加した半減期を有する治療用タンパク質およびそれを調製する方法
JP2019151643A (ja) * 2011-05-27 2019-09-12 バクスアルタ ゲーエムベーハー 増加した半減期を有する治療用タンパク質およびそれを調製する方法
JP2021183636A (ja) * 2011-05-27 2021-12-02 バクスアルタ ゲーエムベーハー 増加した半減期を有する治療用タンパク質およびそれを調製する方法

Also Published As

Publication number Publication date
WO2007050581A3 (en) 2007-11-08
US7345150B2 (en) 2008-03-18
EP1940474A4 (en) 2011-05-25
EP1940474A2 (en) 2008-07-09
CA2627155A1 (en) 2007-05-03
US20060057070A1 (en) 2006-03-16
US20080247958A1 (en) 2008-10-09
WO2007050581A2 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
US20080247958A1 (en) Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
EP1011710B1 (en) Methods and compositions for optimization of oxygen transport by cell-free systems
Bingaman et al. Fluorescent dyes modify properties of proteins used in microvascular research
TWI377947B (en) A method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
CA2282407C (en) Methods and compositions for optimization of oxygen transport by cell-free systems
Kuzu et al. Role of integrins and intracellular adhesion molecule-1 in lung injury after intestinal ischemia-reperfusion
US7884068B2 (en) Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
Rehman et al. Methylglyoxal mediated glycation leads to neo-epitopes generation in fibrinogen: Role in the induction of adaptive immune response
Luo et al. Cytosolic perfluorocarbon delivery to platelets via albumin for antithrombotic therapy
US20100216695A1 (en) Second generation low oxygen affinity pegylated hemoglobins as oxygen-carrying plasma expanders
US7037895B2 (en) Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
CN118718022A (zh) 一种腹腔镜肝切除手术导航用近红外荧光显影剂及其制备方法和应用
US7605130B2 (en) Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
Hess Blood substitutes for surgery and trauma: efficacy and toxicity issues
Vandegriff et al. Impact of acellular hemoglobin‐based oxygen carriers on brain apoptosis in rats
Yan et al. Hydroxyethyl starch–bovine hemoglobin conjugate as an effective oxygen carrier with the ability to expand plasma
Munoz et al. Toxic side-effects of diaspirin cross-linked human hemoglobin are attenuated by the apohemoglobin-haptoglobin complex
JP2001510569A (ja) 血漿容積の測定
JP2012522782A (ja) 医薬のためのプラットフォームとしての、少なくとも１つの保護されたチオール領域を有するｐｅｇ−アルブミン組成物
Londono et al. Glomerular handling of circulating glycated albumin in the normal mouse kidney
TWI445543B (zh) 一種用以治療眼部脈絡膜血管新生之醫藥組合物
WO2016077825A1 (en) Conjugated proteins
US20240228566A1 (en) Compositions and methods for vascular protection after myocardial ischemia
Bundgaard et al. Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins.
Unal et al. Effects of lidocaine on membrane stabilization in harvested vein graft storage.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120510

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130809